WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed at an Analyst and Investor Event this evening, Monday, June 5, 2017. These data are from posters and presentations at the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.
A live webcast of the event will begin on June 5, 2017 at 7:30 p.m. CT (8:30 p.m. ET) and will be accessible via www.incyte.com in the Investors section under “Events and Presentations”. Investors interested in listening to the live webcasts should log on before the start time to download any required software.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.